Welcome to Endpoints News’ manufacturing news briefs, where we bring you essential updates on new builds, collaborations, recalls and more.
NightHawk is to become a pure-play CDMO by ending its R&D activities and divesting its biodefense subsidiary Elusys, according to a Tuesday announcement. NightHawk will now only focus on its manufacturing subsidiary Scorpius BioManufacturing, which has generated over $20 million in revenue during its first year of operations. Elusys will be taken over by a private company owned by NightHawk CEO Jeff Wolf.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.